Observational studyBreast cancer research and treatment2026
A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy.
Observational study in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe patient characteristics, treatment patterns and real-world survival in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who received chemotherapy in the post-endocrine therapy (ET) setting where cytotoxic agents are the mainstay of treatment.
methodsThis retrospective, observational cohort study utilized data from the US nationwide Flatiron Health Research Database. Women aged ≥ 18 years with HR+/HER2 - mBC who received chemotherapy post-ET from January 1, 2015, to December 31, 2024, were included. Patient characteristics, treatment patterns, real-world overall survival (rwOS), and time to next treatment or death (rwTTNTD) were described post-ET.
results5041 patients were included; median age was 63 years at mBC diagnosis. Most were non-Hispanic White (63%) and treated in the community setting (82%) and had Eastern Cooperative Oncology Group performance status 0-1 (59%) at the start of first-line treatment (1L) post-ET, recurrent mBC (68%), and ≥ 2 prior lines of ET-based treatment in the mBC setting (65%). Median time from mBC diagnosis to 1L post-ET was 19 months. Most patients (97%) received chemotherapy 1L post-ET. Median (95% CI) rwOS from start of 1L post-ET was 13.5 (13.0-14.1) months. 30% of patients who initiated 1L post-ET did not survive to the next treatment line; there was a decrease in rwOS with each subsequent treatment. Similar findings were observed for rwTTNTD.
conclusionsThese findings reinforce the high unmet need in patients with HR+/HER2 - mBC whose disease has become resistant to ET, highlighting the need for effective treatments in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.